Grit Biotechnology

This early-phase study is testing a new cell therapy called GT801 in adults with advanced blood cancers or autoimmune anemia that has not responded to standard treatments. The main goals are to check if the treatment is safe and to see early signs of whether it helps control the …

This early-stage study is testing a new cell therapy called GT719 in adults with several types of immune-mediated kidney diseases that have not responded well to standard treatments. The main goals are to find a safe dose and see how well the body tolerates the treatment, while a…

This early-stage study is testing the safety of a personalized immune cell therapy called TIL injection (GT101) for adults with metastatic or recurrent solid tumors. Researchers will collect a patient's own tumor-fighting immune cells, grow them in a lab, and reinfuse them back i…

This early study is testing a new, personalized treatment for people with advanced head and neck cancer that has come back or spread. Doctors take a patient's own immune cells from a tumor, grow billions of them in a lab, and infuse them back along with a standard immunotherapy d…

This early-stage study is testing a new, 'off-the-shelf' cell therapy called GT719 in adults with B-cell blood cancers (like certain leukemias and lymphomas) that have come back or not responded to other treatments. The main goals are to see if the treatment is safe, what side ef…

This early-stage study is testing the safety of an experimental cell therapy called GT719 injection in people with moderate to severe autoimmune diseases that haven't responded to standard treatments. The study will enroll 10 participants with conditions like lupus, scleroderma, …

This early-stage study is testing the safety and initial effectiveness of an experimental cell injection called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The trial will enroll 36 adults who developed cGVHD after…

This is an early-stage study to test the safety and initial effects of a new cell therapy called GT719. It is for adults with neurological autoimmune diseases that have come back or not improved with standard treatments. Researchers will give participants an infusion of GT719 cel…

This study is testing a new personalized cell therapy called GT307 for adults with advanced solid tumors that have not responded to standard treatments. Doctors take a patient's own immune cells from a tumor, grow large numbers of them in a lab, and then infuse them back into the…

This early-stage study is testing a new cell therapy called GT801 for people with moderate-to-severe autoimmune diseases that haven't responded to standard treatments. The trial will enroll 22 adults with conditions like lupus, scleroderma, or inflammatory muscle diseases to chec…

This early-stage study is testing a new cell-based treatment called GT719 injection for adults with B-cell blood cancers that have come back or haven't responded to other treatments. The main goals are to find a safe dose and see if the treatment helps shrink the cancer. About 46…